A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.
Also called NCT07833098
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
- Registry
-
NCT07833098
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07833098. Randomized; quadruple masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
- Condition
- Hypertension
- Condition
- Resistant Hypertension
- Condition
- Uncontrolled Hypertension
- Intervention (Drug)
- VB19055 Dose A QD
- Intervention (Drug)
- VB19055 Dose B QD
- Intervention (Drug)
- VB19055 Dose C QD
- Intervention (Drug)
- VB19055 placebo QD
- Lead sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Record details
- Record id
cardio:ct-nct07833098- Content hash
66e41694037190f3950904c22c512ce3270e1fe1e320c1c8e2919f16c9e0f809